BEAM - Editas upgraded at Citi ahead of FDA AdCom on gene editing therapy
2023-10-24 08:05:14 ET
More on Beam, CRISPR, etc.
- Beam: Opportunity Based On SCD Data Readout In 2024
- Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy
- Editas Medicine: A Mispriced Contender In The Gene Editing Arena
- Beam extends slide as Leerink downgrades on restructuring plans
- Vertex Pharmaceuticals executive chairman disposes stake worth $4.85M
For further details see:
Editas upgraded at Citi ahead of FDA AdCom on gene editing therapy